MOMELOTINIB AND CITARINOSTAT: CO-TARGETING JAK2/STAT3 AND HDAC6 IN LYMPHOID MALIGNANCIES, A NEW POTENTIAL THERAPEUTIC COMBINATION

被引：0
|
作者：
Cosenza, M. [1 ]
Civallero, M. [1 ]
Sacchi, S. [1 ]
Pozzi, S. [1 ]
机构：
[1] Univ Modena & Reggio Emilia, Dipartimento Med Diagnost Clin & Sanita Pubbl, Modena, Italy
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO105
引用
收藏
页码：S118 / S119
页数：2
相关论文
共 50 条
  • [21] PRRX1 promotes colorectal cancer stemness and chemoresistance via the JAK2/STAT3 axis by targeting IL-6
    Zhong, Longzhu
    Tan, Wanlin
    Yang, Qianqiong
    Zou, Zhaowei
    Zhou, Rui
    Huang, Yongsheng
    Qiu, Zhenghua
    Zheng, Kehong
    Huang, Zonghai
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (06) : 2989 - 3008
  • [22] Combination of Youhua Kuijie Prescription and sulfasalazine can alleviate experimental colitis via IL-6/JAK2/STAT3 pathway
    Tang, Lili
    Liu, Yuedong
    Tao, Hongwu
    Feng, Wenzhe
    Ren, Cong
    Shu, Yuping
    Luo, Ruijuan
    Wang, Xiangyi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [23] JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for co-targeting these pathways in metastatic breast cancer
    Britschgi, Adrian
    Andraos, Rita
    Brinkhaus, Heike
    Klebba, Inna
    Murakami, Masato
    Romanet, Vincent
    Mueller, Urs
    Radimerski, Thomas
    Bentires-Alj, Mohamed
    CANCER RESEARCH, 2013, 73 (08)
  • [24] Modulating JAK2/STAT3 signaling by quercetin in Qiling Baitouweng Tang: a potential therapeutic approach for diffuse large B-cell lymphoma
    Zhan, Xin-Zhuo
    Wei, Tian-Hua
    Huang, Chen
    Yu, Hui
    Chen, Xiao-Li
    Kong, Xiang-Tu
    Shang, Zhi-Hao
    Sun, Shan-Liang
    Lu, Meng-Yi
    Ni, Hai-Wen
    MOLECULAR DIVERSITY, 2024,
  • [25] The combination of soluble IL-6 receptor and IL-6 induces tyrosine phosphorylation of GP130, Jak1, Jak2 and STAT3 in human platelets.
    Oda, A
    Nakahata, T
    Druker, BJ
    Ozaki, K
    Tsuji, K
    Yasukawa, K
    Kato, T
    Handa, M
    Ikeda, Y
    BLOOD, 1997, 90 (10) : 3018 - 3018
  • [26] Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy
    Jhaveri, Komal
    Teplinsky, Eleonora
    Silvera, Deborah
    Valeta-Magara, Amanda
    Arju, Rezina
    Giashuddin, Shah
    Sarfraz, Yasmeen
    Alexander, Melissa
    Darvishian, Farbod
    Levine, Paul H.
    Hashmi, Salman
    Zolfaghari, Ladan
    Hoffman, Heather J.
    Singh, Baljit
    Goldberg, Judith D.
    Hochman, Tsivia
    Formenti, Silvia
    Esteva, Francisco J.
    Moran, Meena S.
    Schneider, Robert J.
    CLINICAL BREAST CANCER, 2016, 16 (02) : 113 - 122
  • [27] Proffered Paper: JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for co-targeting these pathways in metastatic breast cancer
    Britschgi, A.
    Andraos, R.
    Brinkhaus, H.
    Klebba, I.
    Romanet, V.
    Mueller, U.
    Murakami, M.
    Radimerski, T.
    Bentires-Alj, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S7 - S7
  • [28] Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer
    Kim, Min Soo
    Lee, Won Sung
    Jeong, Joon
    Kim, Seong-Jin
    Jin, Wook
    ONCOTARGET, 2015, 6 (37) : 40158 - 40171
  • [29] Interleukin-6-induced satellite cell proliferation is regulated by induction of the JAK2/STAT3 signalling pathway through cyclin D1 targeting
    Kurosaka, M.
    Machida, S.
    CELL PROLIFERATION, 2013, 46 (04) : 365 - 373
  • [30] Novel Indole-fused benzooxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals
    Singh, Ashok K.
    Bhadauria, Archana S.
    Kumar, Umesh
    Raj, Vinit
    Rai, Amit
    Kumar, Pranesh
    Keshari, Amit K.
    Kumar, Dinesh
    Maity, Biswanath
    Nath, Sneha
    Prakash, Anand
    Saha, Sudipta
    SCIENTIFIC REPORTS, 2018, 8
12345